SCIndeks - Article

Article

email this article

add to mySelection (0)

full text

Abstract

Inhibitors of the renin-angiotensin system are considered as the first line antihypertensive drugs in therapy of incipient diabetic nephropathy (DN). The aim od this study was to investigate the effect of angiotensin II receptor blockers-valsartan, on plasma lipid profiles in diabetic patients with persistent microalbuminuria (McA). Among the group of 67 type 1 diabetic patients, we choose 20 normotensive patients with incipient DN, who were divided into two groups (10 patients each): valsartan group, treated with 80 mg valsartan daily during 6 months, and the group treated with placebo during the same period. After 6 months therapy, the reduced values of total cholesterol (5.35 “ 1.19 vs 5.20 “ 1.94 mmol/L), triglyceride (1.42 “ 0.79 vs 1.21 “ 0.69 mmol/L) and LDL-cholesterol fraction (3.41 “ 1.21 vs 3.31 “ 0.84 mmol/L) were registrated in valsartan group. While compared with placebo gruop, reduction in serum triglyceride values reached statistical singificancy (-15.5%; p<0.05). Patients with persistent McA have a higher risk of cardiovascular morbidity and mortality than diabetics without this complication. These results, therefore, suggests beneficial effect of valsartan on lipid metabolism, additionally to secondary prevention of chronic diabetic complications.

Keywords

diabetes mellitus type 1; diabetic nephropathy; lipoproteins; antihypertensive agents; reninangiotensin system; valsartan

	References
	*** (1996) Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. The Microalbuminuria Captopril Study Group. Diabetologia, 39(5): 587-93
1	American Diabetes Association (2002) Treatment of hypertension in adults with diabetes. Diabetes Care, 25(1): 199-201
3	Andersen, S., Blouch, K., Bialek, J., Deckert, M., Parving, H.H., Myers, B.D. (2000) Glomerular permselectivity in early stages of overt diabetic nephropathy. Kidney Int, 58(5): 2129-37
	Bak, J.F., Gerder, L.U., Sorensen, N.S., Pedersen, O. (1992) Effects of perindopril on insulin sensitivity and plasma lipid profile in the hypertensive non-insulin-dependent diabetic patients. Am J Med, 92 (Suppl 4B):, S69-S72
1	Bilous, R., Marshall, S. (1997) Clinical aspects of nephropathy. in: Alberti K., Yimmet P., De Fronzo R.A. (ed.) International Textbook of Diabetes Mellitus, New York, itd: Wiley, str. 97-108
9	Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care, 26 Suppl 1: S5-20
1	Gradman, A.H. (1999) Long-term benefits of angiotensin II blockade: Is the consensus changing?. Am J Cardiol, 84(10A): 16S-21S
	Haffner, S.M., American Diabetes Association (2003) Management of dyslipidemia in adults with diabetes. Diabetes Care, 26 Suppl 1: S83-6
	Hope, S., Brecher, P., Chobanian, A.V. (1999) Comparasion of the effect of AT1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis. Am J Hypertens, 12, str. 28-34
	Inada, Y., Murakami, M., Tazawa, S., Akahane, M. (2000) KRH-594, a new angiotensin AT1 receptor antagonist, ameliorates nephropathy and hyperlipidaemia in diabetic spontaneously hypertensive rats. Clin Exp Pharmacol Physiol, 27(4): 270-6
1	Kowala, M.C., Grove, R.I., Aberg, G. (1994) Inhibitors of angiotensin converting enzyme decrease early atherosclerosis in hyperlipidemic hamsters. Fosinopril reduces plasma cholesterol and captopril inhibits macrophage-foam cell accumulation independently of blood pressure and plasma lipids. Atherosclerosis, 108(1): 61-72
3	Lewis, E.J., Hunsicker, L.G., Clarke, W.R., Berl, T., Pohl, M.A., Lewis, J.B., Ritz, E., Atkins, R.C., Rohde, R., Raz, I., Collaborative, S.G. (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med, 345(12): 851-60
1	Li, J., Hirose, N., Kawamura, M., Arai, Y. (1999) Antiatherogenic effect of angiotensin converting enzyme inhibitor (benazepril) and angiotensin II receptor antagonist (valsartan) in the cholesterol-fed rabbits. Atherosclerosis, 143(2): 315-26
	Meigs, J.B., D'Agostino, R.B., Nathan, D.M., Rifai, N., Wilson, P.W.F., Framingham Offspring Study (2002) Longitudinal association of glycemia and microalbuminuria: The Framingham Offspring Study. Diabetes Care, 25(6): 977-83
3	Mogensen, C.E., Neldam, S., Tikkanen, I., Oren, S., Viskoper, R., Watts, R.W., Cooper, M.E. (2000) Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study. BMJ, 321(7274): 1440-4
1	Molitch, M.E., DeFronzo, R.A., Franz, M.J., Keane, W.F., Mogensen, C.E., Parving, H., American Diabetes Association (2003) Diabetic nephropathy. Diabetes Care, 26 Suppl 1: S94-8
	Morrish, N.J., Wang, S.L., Stevens, L.K., Fuller, J.H., Keen, H. (2001) Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia, 44 Suppl 2: S14-21
	Nickenig, G. (2002) Central role of the AT(1)-receptor in atherosclerosis. J Hum Hypertens, 16 Suppl 3: S26-33
	Nielsen, F.S., Rossing, P., Gall, M.A., Skott, P., Smidt, U.M., Parving, H.H. (1994) Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes, 43(9): 1108-13
1	O'Hare, P., Bilbous, R., Mitchell, T., O', C.C.J., Viberti, G.C., Ace-Inhibitor Trial to Lower Albuminuria in Normotensive Insulin-Dependent Subjects Study Group (2000) Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: Results of a randomized controlled trial. Diabetes Care, 23(12): 1823-9
	Rachmani, R., Lidar, M., Brosh, D., Levi, Z., Ravid, M. (2000) Oxidation of low-density lipoprotein in normotensive type 2 diabetic patients. Comparative effects of enalapril versus nifedipine: A randomized cross-over over study. Diabetes Res Clin Pract, 48(2): 139-45
1	Rossing, K., Christensen, P.K., Jensen, B.R., Parving, H. (2002) Dual blockade of the renin-angiotensin system in diabetic nephropathy: A randomized double-blind crossover study. Diabetes Care, 25(1): 95-100
	Ruilope, L.M. (1999) The kidney as part of the cardiovascular system. J Cardiovasc Pharmacol, 33 Suppl 1: S7-10; dis
	Sanz, M., Ganado, P., Tejerina, T. (2002) Two angiotensin AT1 receptor antagonists, irbesartan and losartan, effects in cholesterol-fed rabbits. Eur J Pharmacol, 442(1-2): 99-106
	Sasso, F.C., Carbonara, O., Persico, M., Iafusco, D., Salvatore, T., D'Ambrosio, R., Torella, R., Cozzolino, D. (2002) Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: A randomized double-blind placebo-controlled crossover study. Diabetes Care, 25(11): 1909-13
	Strawn, W.B., Chappell, M.C., Dean, R.H., Kivlighn, S., Ferrario, C.M. (2000) Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation, 101(13): 1586-93
1	Tatti, P., Pahor, M., Byington, R.P., di Mauro, P., Guarisco, R., Strollo, G., Strollo, F. (1998) Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care, 21(4): 597-603
2	The EUCLID Study group (1997) Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group. Lancet, 349(9068): 1787-92
	Williams, B. (2000) The renin angiotensin system in the pathogenesis of diabetic comlications. in: Mogensen C.E. (ed.) The kidney and hypertension in diabetes mellitus, Boston, Dordrecht, London: Kluwer Academic Publishers, str. 645-54
	Zhou, M.S., Adam, A., Rail, L. (2001) Interaction among angiotensin II, nitric oxide and oxidative stress. JRAAS, 2 (Suppl 1), S59-S63

Article

Abstract

Keywords

References